Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Studies from University of Zurich have provided new data on breast cancer
December 11th, 2008
"Breast cancer central nervous system (CNS) metastases are an increasingly important problem because of high CNS relapse rates in patients treated with trastuzumab and/or taxanes. We evaluated data from 2887 node-positive breast cancer patients randomised in the BIG 02-98 trial comparing anthracycline-based adjuvant chemotherapy (control arms) to anthracycline-docetaxel-based sequential or concurrent chemotherapy (experimental arms)," investigators in Zurich, Switzerland report. "After a median follow-up of 5 years, 403 patients had died and detailed information on CNS relapse was collected for these patients. CNS relapse occurred in 4.0% of control patients and 3.7% of...
Source: Women's Health Weekly (2008-12-11)
|
